News & Events about Chromadex Corp.
On June 13th, ChromaDex Corp. (NASDAQ:CDXC), a global authority on nicotinamide adenine dinucleotide (NAD+) research and healthy aging, celebrated the 10th anniversary of its award-winning ChromaDex External Research Program (CERP). Through CERP, independent scientists and investigators from some...
StockNews.com upgraded shares of ChromaDex (NASDAQ:CDXC Get Rating) from a buy rating to a strong-buy rating in a report published on Friday morning. Several other research analysts have also recently weighed in on CDXC. LADENBURG THALM/SH SH dropped their price target on shares of ChromaDex from $7...
ChromaDex Corp. (NASDAQ:CDXC) (the Company) a global bioscience company dedicated to healthy aging, today announced that senior management will participate at the 35th annual ROTH Capital Partners Conference at the Ritz-Carlton in Dana Point, CA. The Annual ROTH Conference is one of the largest in...
ChromaDex Corp. (NASDAQ:CDXC) (the Company), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 8, 2023 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and fiscal year, which ended December 31, 2022. The...
ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, holds an exclusive license from Queens University Belfast for methods of making nicotinamide riboside (NR) and related derivatives, some of the most efficient nicotinamide adenine dinucleotide (NAD+) precursors...